MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies

MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies

This research study is evaluating the feasibility of conducting cancer genetic testing using healthy skin cells among participants with a diagnosis of a blood cancer. Additionally, investigators will evaluate how often participants with blood cancers are found to have risk for cancer based on family genes.

The purpose of this prospective, non-randomized, non-therapeutic, single arm study is to determine the feasibility and benefit of performing genetic testing for all participants with a blood cancer diagnosis regardless of clinical suspicion.

Research study procedures include screening for eligibility, in-clinic visits, questionnaires, and skin punch biopsies. Participants will receive germline genetic testing with a comprehensive hereditary cancer gene panel.

It is expected that about 200 individuals with blood cancer will take part in this research study.

Inclusion Criteria:

• Age of 18 years or older
• Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening.
• Ability to understand and provide a signed and completed consent document in English or Spanish.

Exclusion Criteria:

• Patients with who cannot safely undergo skin biopsy as adjudicated by the study team.
• Patients who have previously undergone germline genetic testing for predisposition to myeloid malignancies